A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|6|804-813

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.6, 2015-09, pp. : 804-813

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 219-227

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

By  

Acta Haematologica, Vol. 133, Iss. 4, 2014-12 ,pp. : 336-346

Karger

Access to resources Recommend Favorite

Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E60-E65

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 342-347

John Wiley & Sons Inc

Access to resources Recommend Favorite